论文部分内容阅读
目的观察金龙胶囊治疗晚期原发性肝癌22例的临床疗效。方法将符合纳入标准的44例患者随机分为治疗组22例,对照组22例。治疗组口服金龙胶囊至少3个月,对照组采用最佳支持治疗。对比两组生活质量、生存期。结果治疗组部分缓解率为13.63%,对照组为0,但差别无统计学意义(P>0.05)。治疗组临床受益率为77.27%,高于对照组的36.36%,差别有统计学意义(P<0.005)。治疗组病情进展率为22.73%,低于对照组的63.64%,差别有显著意义(P<0.005)。治疗组生活质量改善方面明显优于对照组,两组均未发生明显不良反应。结论与对照组治疗相比,金龙胶囊可提高原发性肝癌治疗有效率,提高临床受益率,改善患者的生存质量,长期服用金龙胶囊可延长肝癌患者的生存期,无明显不良反应,是治疗晚期原发性肝癌较好的中药制剂。
Objective To observe the clinical effect of Jinlong Capsule in treating 22 cases of advanced primary liver cancer. Methods Forty-four patients who met the inclusion criteria were randomly divided into treatment group (n = 22) and control group (n = 22). The treatment group oral Jinlong capsule at least 3 months, the control group with the best supportive treatment. Compare the two groups of quality of life, survival. Results The response rate was 13.63% in the treatment group and 0 in the control group, but the difference was not statistically significant (P> 0.05). The clinical benefit rate of the treatment group was 77.27%, which was higher than that of the control group (36.36%), the difference was statistically significant (P <0.005). The progress rate of the treatment group was 22.73%, which was lower than 63.64% of the control group, the difference was significant (P <0.005). The quality of life in the treatment group was significantly better than that in the control group, and no obvious adverse reactions occurred in both groups. Conclusion Compared with the control group, Jinlong Capsule can improve the treatment efficiency of primary liver cancer, improve the clinical benefit rate and improve the quality of life of patients. Long-term administration of Jinlong Capsule can prolong the survival of patients with liver cancer without obvious adverse reactions and is the treatment Advanced primary liver cancer traditional Chinese medicine preparation.